| | | | |

Cediranib for Mesothelioma: VEGF Inhibitor Fails Another Trial

ByAlex Strauss
cediranib for mesothelioma

Cediranib for mesothelioma appears to be ruled out by another failed clinical trial. 

A new study led by MD Anderson researchers concludes that the VEGF inhibitor causes too many side effects for not enough survival benefit. 

It is a blow to researchers hoping to use cediranib for mesothelioma patients on chemotherapy. 

Cutting Off Tumor Blood Supply

Cediranib is an oral drug made by AstraZeneca. It is part of a class of drugs called VEGF inhibitors. Vascular endothelial growth factor (VEGF) is a signal protein that stimulates blood vessel formation in tumors. Research shows that mesothelioma patients who have higher serum levels of VEGF have a lower chance of survival. 

VEGF inhibitors like cediranib latch onto VEGF receptors inside mesothelioma cells. This blocks cells from receiving VEGF signals. The theory is that cediranib for mesothelioma could keep tumors from growing and spreading. 

Standard mesothelioma chemotherapy is only moderately effective. MD Anderson researchers hoped that giving cediranib along with chemotherapy would enhance the effect and help patients live longer. A Phase I study of the combination looked promising.

Chemotherapy + Cediranib for Mesothelioma

There were 92 mesothelioma patients in the Phase II study. Three out of the four of them had the epithelioid mesothelioma subtype. The rest had sarcomatoid or biphasic mesothelioma.

The patients in the study were not eligible for mesothelioma surgery. Instead, they all got standard chemotherapy with cisplatin and Alimta. 

Half of the patients also got a placebo and the other half took oral cediranib for mesothelioma along with chemotherapy.

“The cediranib arm had more grade 3 and 4 diarrhea, dehydration, hypertension, and weight loss,” reports lead researcher Anne Tsao, MD. 

Among the patients that received cediranib for mesothelioma, it took about two months longer for their cancer to start growing again. But they did not live any longer than the placebo group. 

The research team concludes that the downsides of using cediranib for mesothelioma outweigh the upsides. 

“The cediranib toxicity profile and small incremental survival benefit precludes additional development in MPM,” they write.

Other Trials Produced Similar Results

Several previous trials of cediranib for mesothelioma have also been disappointing. 

A 2012 University of Chicago study tested cediranib as a stand-alone mesothelioma treatment. The study showed that the drug did have an effect on mesothelioma tumors when the dose was high enough. But patients who took the higher dose also got much sicker.

That study included 51 mesothelioma patients enrolled at nine different centers. It found that cediranib for mesothelioma caused blood clots in the lungs, confusion, seizures, and vision loss.

Studies of cediranib for other cancers suggest that it does not usually work well by itself. Current studies are focused on cediranib’s potential to boost other cancer treatments. 

Sources:

Tsao, A, et al, “Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)”, August 6, 2019, Journal of Clinical Oncology, https://ascopubs.org/doi/abs/10.1200/JCO.19.00269

Similar Posts

  • | |

    Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

    ByAlex Strauss

    Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    ByAlex Strauss

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    ByAlex Strauss

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…